Aehr Test Systems
AEHR
$91.30
+10.88%
Aehr Test Systems designs and manufactures advanced test and burn-in equipment for logic, optical, and memory integrated circuits, serving the semiconductor manufacturing industry. The company is a niche player specializing in high-reliability testing, particularly for the demanding automotive and mobility markets, positioning itself as a critical supplier for quality assurance in safety-critical applications. The current investor narrative is intensely focused on its role in the AI infrastructure build-out, with recent news highlighting a surge in the stock price following a major new order and $37.2 million in bookings, signaling strong validation of its technology and robust future demand expectations in a booming sector.…
AEHR
Aehr Test Systems
$91.30
Related headlines
Investment Opinion: Should I buy AEHR Today?
Rating & Thesis: The stock is a Hold with a Sell-on-Strength bias for existing investors and a high-risk Speculative Buy only for aggressive, risk-tolerant investors with a very long time horizon. The core thesis is that AEHR represents a binary, high-stakes bet on the realization of its massive projected revenue growth, which is not yet reflected in its deteriorating fundamentals.
Supporting Evidence: The recommendation is anchored by the extreme disconnect between valuation and current performance: a trailing PS of 4.79 on declining sales, a negative P/E of -72.17, and deeply negative free cash flow. While the analyst-projected revenue of $196.1M implies a compelling forward PS, the company must first reverse a -26.53% YoY revenue decline. The stock's 971% 1-year gain and beta of 3.27 indicate extreme momentum and volatility, not stability. The balance sheet's strength (Current Ratio: 5.68) is a positive but insufficient offset to the operational weaknesses.
Risks & Conditions: The two biggest risks are the failure to achieve forecasted revenue growth and continued margin deterioration leading to greater losses. This Hold would upgrade to a Buy only upon concrete evidence of the revenue ramp, such as consecutive quarters of revenue accelerating towards the $50M+ quarterly run-rate and a return to positive operating cash flow. It would downgrade to a Sell if revenue continues to decline sequentially or if the company announces a dilutive equity offering. Relative to its own volatile history and the lack of profitable peers, the stock is severely overvalued on current fundamentals but could be undervalued if the transformative growth occurs.
Sign up to view all
AEHR 12-Month Price Forecast
The AI assessment is neutral due to the extreme dichotomy between transformative potential and present reality. The confidence is low because the investment thesis hinges entirely on a future event—the materialization of forecasted revenue—that is unprecedented in scale for the company. The stock's 3.27 beta and parabolic rise make it a tactical trading vehicle rather than a fundamental investment at this price. The stance would upgrade to bullish only upon sustained, quarter-over-quarter revenue acceleration towards the $50M+ range. It would turn bearish if the next earnings report shows further revenue contraction or guidance reduction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aehr Test Systems's 12-month outlook, with a consensus price target around $118.69 and implied upside of +30.0% versus the current price.
Average Target
$118.69
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$73 - $119
Analyst target range
Analyst coverage for Aehr Test Systems is extremely limited, with only one analyst providing estimates, indicating insufficient coverage for a robust consensus. The single analyst estimates revenue of $196.1 million and EPS of $1.14 for the upcoming period, which represents a monumental increase from current levels and is the cornerstone of the bullish thesis. The lack of a broad analyst consensus and target price means price discovery is highly speculative and driven by retail and institutional momentum rather than fundamental price targets. The minimal coverage is typical for a small-cap, high-volatility story stock and contributes to the extreme price swings, as seen in the beta of 3.27. Recent institutional ratings show mixed sentiment; William Blair upgraded the stock from 'Market Perform' to 'Outperform' on March 2, 2026, a notably bullish signal, while Craig-Hallum downgraded from 'Buy' to 'Hold' back in March 2024. The most recent actions from Freedom Broker have consistently been 'Hold'. This pattern suggests analyst views are diverging, with the upgrade from William Blair likely tied to the recent large AI-related order, but the overall thin coverage underscores the high uncertainty and speculative nature of the investment.
Bulls vs Bears: AEHR Investment Factors
The bull case for AEHR is a pure narrative-driven bet on explosive future growth, validated by a recent major AI-related order and a single analyst's projection for a 20x revenue ramp. The bear case is grounded in the harsh reality of declining sales, significant losses, negative cash flow, and a valuation that has detached from all current fundamentals. Currently, the bear side has stronger evidence based on the company's present financial performance. The single most important tension in the investment debate is the timing and certainty of the projected revenue transformation from $9.88 million to $196.1 million. If this growth materializes as forecast, the stock could be cheap; if it is delayed or fails, the current price represents a massive speculative bubble.
Bullish
- Massive AI-Driven Order Bookings: Recent news highlights $37.2 million in new bookings, a major order that validates Aehr's role in the AI infrastructure build-out. This signals robust future demand for its specialized test and burn-in equipment, providing a tangible catalyst for the explosive 971% 1-year stock surge.
- Analyst Projecting Transformative Revenue: A single analyst projects revenue to leap to $196.1 million and EPS of $1.14 for the upcoming period. This represents a nearly 20x increase from the last quarter's $9.88 million revenue, forming the core of the growth narrative that justifies the current market cap.
- Strong Balance Sheet with Low Debt: The company has a robust current ratio of 5.68 and a minimal debt-to-equity ratio of 0.09. This strong liquidity and lack of financial leverage provide a significant buffer to fund operations and growth without the immediate risk of a credit crunch.
- Niche Leadership in High-Growth Markets: Aehr specializes in high-reliability testing for the automotive and AI semiconductor markets, which are experiencing secular growth. Its positioning as a critical supplier for safety-critical applications creates a potential long-term moat in a demanding segment.
Bearish
- Severe Revenue Contraction and Losses: The most recent quarterly revenue of $9.88 million represents a -26.53% year-over-year decline, and the company posted a net loss of $3.23 million with an operating margin of -49.24%. This starkly contrasts with the growth narrative and raises execution risks.
- Extreme Valuation Disconnect from Fundamentals: The stock trades at a trailing PS ratio of 4.79, but this is against depressed sales. The forward valuation is entirely speculative, hinging on a 20x revenue ramp that has not yet materialized. The negative P/E and P/CF ratios (-72.17 and -38.14) confirm the lack of current profitability.
- Negative Cash Flow and Profitability Metrics: Free cash flow for the trailing twelve months is -$11.91 million, and operating cash flow last quarter was -$1.39 million. With a negative ROE of -3.18% and ROA of -6.10%, the company is burning cash and not generating returns on capital.
- Gross Margin Compression and Volatility: Quarterly gross margin compressed sharply to 25.75%, down from the trailing gross margin of 40.54%. This indicates potential pricing pressure, unfavorable product mix, or cost issues, threatening future profitability even if revenue scales.
AEHR Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +971.04%. With a current price of $99.50, it is trading near the top of its 52-week range, approximately 91% of the way from its low of $8.31 to its high of $108.75. This positioning near the highs reflects extraordinary momentum but also indicates the stock is highly extended, raising risks of a sharp pullback if growth expectations falter. Recent momentum has been explosive, with the stock up 35.89% over the past month and 245.01% over the past three months, significantly outpacing the S&P 500's returns of 5.6% and 8.42%, respectively. This acceleration suggests the rally is entering a potentially parabolic phase, though the -6.43% single-day pullback from the previous close of $106.34 may signal the onset of volatility and profit-taking after such a rapid ascent. Key technical support is at the 52-week low of $8.31, though a more relevant near-term level is likely much higher given the vertical move; immediate resistance is at the 52-week high of $108.75. A decisive breakout above $108.75 would signal the continuation of the powerful uptrend, while a breakdown below key moving averages would suggest a deeper correction. The stock's beta of 3.271 indicates it is approximately 227% more volatile than the broader market, which is critical for risk management as it implies amplified moves in both directions.
Beta
3.27
3.27x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$8-$109
Price range past year
Annual Return
+977.9%
Cumulative gain past year
| Period | AEHR Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +5.5% |
| 3m | +171.7% | +7.7% |
| 6m | +350.4% | +12.7% |
| 1y | +977.9% | +27.4% |
| ytd | +312.0% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AEHR Fundamental Analysis
Revenue growth has been volatile but showed a recent sharp contraction, with the latest quarterly revenue of $9.88 million representing a -26.53% year-over-year decline from the prior year's Q2. The multi-quarter trend reveals significant fluctuation, from $18.31 million in Q3 FY25 down to $9.88 million in the most recent quarter, indicating a challenging near-term demand environment despite the long-term growth narrative. Segment data shows Systems revenue of $6.76 million, Contactors at $2.61 million, and Services at $1.59 million for the unspecified period, but the overall trajectory is one of deceleration. The company is currently unprofitable, with a net loss of $3.23 million in the last quarter and a trailing twelve-month net margin of -6.63%. Gross margin for the quarter was 25.75%, a significant compression from the 40.54% gross margin indicated in the valuation data, highlighting potential pricing pressure or product mix issues. The operating margin was -49.24% last quarter, underscoring the operational losses amid declining sales. The balance sheet appears liquid with a strong current ratio of 5.68 and a low debt-to-equity ratio of 0.09, indicating minimal financial leverage. However, cash flow is a major concern; free cash flow for the trailing twelve months is deeply negative at -$11.91 million, and operating cash flow for the last quarter was -$1.39 million. The negative return on equity of -3.18% and return on assets of -6.10% confirm the company is not efficiently generating profits from its capital, leaving it reliant on external financing or its cash balance to fund operations and growth.
Quarterly Revenue
$9884000.0B
2025-11
Revenue YoY Growth
-0.26%
YoY Comparison
Gross Margin
+0.25%
Latest Quarter
Free Cash Flow
$-11907000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AEHR Overvalued?
Given the negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 4.79, while the forward-looking valuation is more complex due to limited analyst data; the estimated revenue for the next period is $196.1 million, which would imply a significantly lower forward PS ratio if achieved, highlighting the market's expectation of a dramatic revenue ramp. Compared to industry averages, data is not available for a direct sector PS comparison, but the stock's valuation is entirely driven by future growth expectations rather than current fundamentals. Historically, the stock's own PS ratio has fluctuated wildly, reaching as high as 69.83 in recent quarters and as low as 7.77 in May 2021. The current PS of 4.79 is near the lower end of its own historical spectrum over the provided data, but this is misleading as it reflects a massive increase in market cap against currently depressed sales. The stock is trading at a premium to its own historical sales multiples when considering the market cap expansion, implying the market is pricing in a transformative growth phase that has yet to materialize in the financials.
PE
-72.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -111x~168x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-296.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's inability to generate profits or positive cash flow while awaiting its projected growth. With a net loss of $3.23 million last quarter, an operating margin of -49.24%, and trailing twelve-month free cash flow of -$11.91 million, Aehr is burning through its balance sheet cash. Gross margin compression from 40.54% to 25.75% in the latest quarter introduces a new risk to future profitability, suggesting the path to scaling may be more costly than anticipated. Revenue concentration and volatility are also evident, with sales declining -26.53% YoY after peaking at $18.31 million in Q3 FY25.
Market & Competitive Risks: The dominant market risk is valuation compression. The stock's price is predicated on flawless execution of a monumental growth story. Any stumble in order conversion, product delays, or a broader semiconductor cycle downturn could trigger a severe derating. With a beta of 3.27, AEHR is hypersensitive to market sentiment shifts and risk-off moves. Competitive risks are inherent in the capital-intensive semiconductor equipment sector, where larger players could develop similar technology. The limited analyst coverage (only one providing estimates) exacerbates price discovery risk, making the stock prone to exaggerated moves on limited information.
Worst-Case Scenario: The worst-case scenario involves the projected $196.1 million revenue failing to materialize due to order cancellations, technological obsolescence, or a sharp downturn in AI/automotive chip demand. Combined with sustained cash burn, this could force dilutive equity financing. In this adverse scenario, the stock could re-test its fundamental lows, not just its 52-week technical low. A realistic downside could see the stock fall -60% or more from the current $99.50, approaching price levels seen before the AI narrative took hold, potentially below $40, as the market reprices it based on its current unprofitable, sub-$10M quarterly revenue run-rate.
FAQ
The key risks are: 1) Execution Risk: The company must grow revenue nearly 20x from current levels to meet the single analyst's forecast; failure would collapse the narrative. 2) Financial Risk: The company is unprofitable (net margin -6.63%) and burning cash (FCF TTM -$11.91M), with recent gross margin compression to 25.75%. 3) Valuation & Volatility Risk: The stock has a beta of 3.27, meaning it is 227% more volatile than the market, and is trading 91% of its way to its 52-week high after a 971% rally, making it prone to a sharp correction. 4) Limited Visibility Risk: With only one analyst providing estimates, there is minimal institutional research coverage, increasing the potential for misinformation and price gaps.
The 12-month forecast is bifurcated with high uncertainty. The base case (50% probability) sees the stock trading between $60 and $100, as it digests its massive gains and investors await proof of the growth story. The bull case (25% probability), should the $196M revenue forecast materialize, could drive the stock to $150-$200. The bear case (25% probability), if growth stalls, could see a collapse to $30-$50. The most likely scenario is the base case of high volatility within a wide range, as the stock's 3.27 beta and narrative-driven price will react sharply to each quarterly earnings report and booking announcement.
Based on current fundamentals, AEHR is severely overvalued. It has a negative P/E (-72.17), negative free cash flow (-$11.91M TTM), and declining revenue (-26.53% YoY). The trailing PS ratio of 4.79 is misleading as it prices in future growth that has not occurred. The market is paying a massive premium for the potential to grow revenue from a $9.88M quarterly run-rate to a projected $196.1M annual figure. If that growth is achieved, the stock could be undervalued today. If it is not, the stock is wildly overvalued. The valuation implies near-perfect execution of a transformative growth story.
AEHR is a speculative, high-risk stock that could be a good buy only for a very specific investor profile: those with a high risk tolerance, a long-term horizon, and a conviction that the company will achieve its projected ~20x revenue growth. For most investors, it is not a good buy at current levels. The stock is up 971% in a year, trades near its 52-week high, and has a beta of 3.27, indicating extreme volatility. The 25% probability bear case suggests a potential downside to $30-$50, a -50% to -70% drop. A good entry would require a significant pullback and/or concrete evidence of the revenue ramp materializing.
AEHR is not suitable for short-term trading for most investors due to its extreme volatility (beta 3.27) and lack of dividend income. It is a speculative long-term investment for those betting on a multi-year transformation. The investment thesis requires several quarters, if not years, to play out as the company attempts to scale revenue twentyfold. Given the binary outcome, a minimum holding period of 2-3 years is necessary to see if the growth narrative is validated. However, the high risk and volatility mean any position should be sized appropriately as a small, speculative portion of a portfolio.